Literature DB >> 6660852

Pharmacokinetics and tissue penetration of ciprofloxacin.

B Crump, R Wise, J Dent.   

Abstract

A 500-mg dose of the quinoline ciprofloxacin was administered orally to each of six healthy male volunteers, after which the concentrations of this agent in serum and blister fluid were measured. Absorption appeared to be rapid, with a mean peak level of 2.4 micrograms/ml attained 1.25 h after administration. The serum elimination half-life was 3.9 h. The agent penetrated blister fluid well, the percent penetration being 57%. Urinary recovery of ciprofloxacin was 30%.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6660852      PMCID: PMC185942          DOI: 10.1128/AAC.24.5.784

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Drug therapy. Clinical Pharmacokinetics (first of two parts).

Authors:  D J Greenblatt; J Kock-Weser
Journal:  N Engl J Med       Date:  1975-10-02       Impact factor: 91.245

2.  The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics.

Authors:  R Wise; A P Gillett; B Cadge; S R Durham; S Baker
Journal:  J Infect Dis       Date:  1980-07       Impact factor: 5.226

3.  In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.

Authors:  A Bauernfeind; C Petermüller
Journal:  Eur J Clin Microbiol       Date:  1983-04       Impact factor: 3.267

4.  Norfloxacin (MK-0366) treatment of urinary tract infections in hospitalized patients.

Authors:  G Panichi; A Pantosti; G P Testore
Journal:  J Antimicrob Chemother       Date:  1983-06       Impact factor: 5.790

5.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

6.  Determination of norfloxacin, a new nalidixic acid analog, in human serum and urine by high-performance liquid chromatography.

Authors:  V K Boppana; B N Swanson
Journal:  Antimicrob Agents Chemother       Date:  1982-05       Impact factor: 5.191

  6 in total
  111 in total

1.  Pharmacokinetics and inflammatory fluid penetration of sparfloxacin.

Authors:  J H Johnson; M A Cooper; J M Andrews; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

2.  Spontaneously occurring staphylococcal mutants resistant to clinically achievable concentrations of ciprofloxacin and temafloxacin.

Authors:  A L Barry; M A Pfaller; P C Fuchs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-03       Impact factor: 3.267

3.  Pharmacokinetics of temafloxacin in humans after single oral doses.

Authors:  G R Granneman; P Carpentier; P J Morrison; A G Pernet
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

4.  Penetration of fleroxacin and ciprofloxacin into skin blister fluid: a comparative study.

Authors:  T J Lubowski; C Nightingale; K Sweeney; R Quintiliani; J Zhi
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

5.  Survey: calculation of the characteristics of oral diffusion-controlled release dosage forms related to the drug.

Authors:  I D Rosca; J M Vergnaud
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2010-09       Impact factor: 2.441

Review 6.  Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response.

Authors:  D E Nix; S D Goodwin; C A Peloquin; D L Rotella; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

7.  Susceptibility of multiply antibiotic-resistant pneumococci to the new quinoline antibiotics, nalidixic acid, coumermycin, and novobiocin.

Authors:  M E Gombert; T M Aulicino
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

Review 8.  Quinolones in urology.

Authors:  K T Nielsen; P O Madsen
Journal:  Urol Res       Date:  1989

9.  Ciprofloxacin concentrations in tonsils following single or multiple administrations.

Authors:  N Falser; A Dalhoff; H Weuta
Journal:  Infection       Date:  1988       Impact factor: 3.553

10.  Comparative activities of ciprofloxacin, ticarcillin, and tobramycin against experimental Pseudomonas aeruginosa pneumonia.

Authors:  J B Schiff; G J Small; J E Pennington
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.